Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 29, Issue 7, Pages 925-933Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2009.27.2369
Keywords
-
Categories
Funding
- National Institutes of Health [R01-CA098951, P50-CA083638, R01-CA112162]
- Ovarian Cancer Immunotherapy Initiative
Ask authors/readers for more resources
In the past decade, we have witnessed important gains in the treatment of ovarian cancer; however, additional advances are required to reduce mortality. With compelling evidence that ovarian cancers are immunogenic tumors, immunotherapy should be further pursued and optimized. The dramatic advances in laboratory and clinical procedures in cellular immunotherapy, along with the development of powerful immunomodulatory antibodies, create new opportunities in ovarian cancer therapeutics. Herein, we review current progress and future prospects in vaccine and adoptive T-cell therapy development as well as immunomodulatory therapy tools available for immediate clinical testing. J Clin Oncol 29: 925-933. (C) 2010 by American Society of Clinical Oncology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available